SCHEMBL7435964

SCHEMBL7435964

O=[N+]([O-])c1c(-c2[c]cccc2)ccc(O)c1O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S100A4 P26447 2/20 0.40
GPR35 Q9HC97 2/20 0.37
CTSB P07858 1/20 0.36
MAPT P10636 3/20 0.35
APEX1 P27695 2/20 0.35
POLB P06746 1/20 0.35
CASP6 P55212 1/20 0.35
GRIN2D O15399 1/20 0.34
GRIN3B O60391 1/20 0.34
GRIN1 Q05586 1/20 0.34
GRIN2A Q12879 1/20 0.34
GRIN2B Q13224 1/20 0.34
GRIN2C Q14957 1/20 0.34
GRIN3A Q8TCU5 1/20 0.34
AURKA O14965 1/20 0.33
GYS1 P13807 1/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
KDM4E B2RXH2 1/20 0.33
ALDH1A1 P00352 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4375599 0.70 ALDH1A1 (0.53) S100A4GPR35MEN1KMT2AALDH1A1
SCHEMBL29652066 0.70 GPR35 (0.54) S100A4GPR35CTSBALDH1A1CYP3A4
SCHEMBL27542455 0.70 CASP6 (0.45) GPR35CTSBMAPTAPEX1POLB
SCHEMBL1396392 0.70 HPGD (0.42) MAPTAPEX1POLBMEN1KMT2A
SCHEMBL9798917 0.68 TDP1 (0.46) S100A4GPR35MAPTMEN1KMT2A
SCHEMBL1451053 0.67 HPGD (0.44) MAPTAPEX1POLBMEN1KMT2A
SCHEMBL11841424 0.67 HSD17B10 (0.50) S100A4MAPTPOLBMEN1KMT2A
SCHEMBL9457324 0.66 ALOX5 (0.50) MAPTMEN1KMT2AKDM4ECYP3A4
SCHEMBL27594357 0.66 NPC1 (0.40) S100A4MAPTAPEX1POLBCASP6
SCHEMBL4028189 0.66 GYS1 (0.37) S100A4GPR35MAPTGRIN2DGRIN3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020037931-A1 Substituted nitrated catechols, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them PORTELA & C.A., S.A. (PT) 2002-03-28 US disclosed
EP-1167341-A1 Substituted nitrated catechols, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them Portela & Ca., S.A. (PT) 2002-01-02 EP disclosed
WO-2001098250-A1 SUBSTITUTED NITRATED CATECHOLS, THEIR USE IN THE TREATMENT OF SOME CENTRAL AND PERIPHERAL NERVOUS SYSTEM DISORDERS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM PORTELA & CA SA (PT) 2001-12-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020037931-A1 Substituted nitrated catechols, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them SLC6A2, COMT, SLC6A3 S100A4 1855/4885GPR35 1196/4885CTSB 3000/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.